This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates. This article will explore how machine learning can be leveraged to optimize generic drugdevelopment… Source
This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drugdevelopers. Reshaping drugdevelopment through CRO/CDMO integration. Integrated CDMO and CRO Services Creates Innovation in Early-Stage DrugDevelopment.
This article outlines key considerations and strategies for developing a sustainable generic drugdevelopment strategy. Pfizer, for example, has been applying green chemistry principles in drugdevelopment for over two decades to reduce waste, minimize resource use, and develop energy-efficient manufacturing processes.
Given macro healthcare influences (eg, economic uncertainty, environmental changes) and the numerous available treatments for major diseases, drugdevelopers may need to reassess their therapeutic strategies. This has led drugdevelopers to unintentionally limit their potential within chosen therapeutic spaces.
Breaking Down Barriers: The Power of Global Research Collaborations in Generic DrugDevelopment As the world grapples with the complexities of healthcare, one thing is clear: the need for innovative solutions has never been more pressing. The benefits of international collaborations in generic drugdevelopment are multifaceted.
The pharmaceutical industry is undergoing significant transformations, particularly in the realm of generic drugdevelopment. Recent trends and advancements in technology, research, and collaboration are reshaping the landscape of generic drugdevelopment, leading to new opportunities and challenges for pharmaceutical companies.
Accelerating Generic DrugDevelopment: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drugdevelopment. The generic drugdevelopment process involves several stages, from patent research to regulatory approvals.
Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy.
The regulatory environment in Japan for generic drugdevelopment is complex and has undergone significant changes in recent years. New Drug Application (NDA) : Needed for marketing approval of new drugs. Abbreviated New Drug Application (ANDA) : Required for marketing approval of generic drugs.
"Game Changers in Generic DrugDevelopment: What's Next? As the pharmaceutical industry continues to evolve, one thing is clear: the future of generic drugdevelopment is about to get a whole lot more interesting. Read the full article here: [link] #GenericDrugs #PharmaInnovation #FutureOfPharma"
Regulatory Guidance for Oligonucleotide Bioanalysis in DrugDevelopment pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.
Real-world evidence (RWE) is changing clinical drugdevelopment, bridging the gap between controlled clinical trial environments and the complexities of everyday patient experiences.
Generic drugdevelopment is a complex process that involves rigorous scientific research and regulatory assessments. Food and Drug Administration (FDA) plays a crucial role in ensuring the quality and efficacy of generic drugs through various programs and guidelines.
Developing treatments for individuals living with rare diseases is critical, but orphan drugdevelopment is laden with unique obstacles that necessitate innovative, multifaceted approaches. RWE is transforming rare disease drugdevelopment, providing the insights needed to overcome unique challenges.
If you use ServiceNow as your knowledge management platform, you might want to make your knowledge articles searchable and accessible from Microsoft Search. By connecting your ServiceNow knowledge articles to Microsoft Search, you can enable your users to find and request them directly from the Microsoft 365 apps.
The review focused on English-language original research and review articles, examining carprofen and its derivatives in terms of their synthesis methods as well as their use as small molecules in various therapeutic applications, both human and veterinary.
Generic drugdevelopment is a complex process that involves not only scientific and medical expertise but also adherence to strict legal and ethical standards. Scientific expertise plays a crucial role in ensuring that generic drugs are held to the same standards of quality, safety, and efficacy as their brand-name counterparts.
As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems. This article delves into the impact of biosimilars on biologic drug… Source
We’re excited to introduce you to two illuminating articles recently featured on CMSWire.com, “The Heart of Composable Architecture,” and “Navigating the Long Tail of Composable in the Martech Landscape” Both articles were penned by Perficient’s own David San Filippo, Sitecore Principal and Sitecore Technology MVP.
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drugdevelopment has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drugdevelopment.
In this article, we will delve into the key criteria for selecting a CDMO, highlighting the essential factors to consider and the importance of effective communication and cultural fit. Your DrugsDevelopment Stage The stage of your drugdevelopment is a critical factor in selecting a CDMO.
The Food and Drug Administration (FDA) and other regulatory bodies have implemented various measures to ensure that generic drugs are equivalent to their brand-name counterparts in terms of quality, safety, and efficacy. This article will delve… Source
The Future of Generic Drugs: How Technology is Revolutionizing the Industry As we continue to navigate the ever-changing landscape of healthcare, one thing is clear: technology is playing an increasingly important role in shaping the future of generic drugdevelopment. Read the full article here: [link]
Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. Your review article discussed the need to study genetically diverse patient samples. Can you expand on that?
The Unseen Hurdles of Generic DrugDevelopment: Lessons Learned As the pharmaceutical industry continues to evolve, one thing remains constant: the pursuit of affordable, high-quality medications for patients worldwide. However, the journey to bringing a generic drug to market is often fraught with challenges.
Drug resistance remains one of the most pressing challenges in oncology drugdevelopment, as it is the leading cause of treatment failure. As researchers look to understand and overcome drug resistance, they need precise, controllable, and scalable models that allow them to isolate and study resistance mechanisms effectively.
These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drugdevelopment.
This is where generic drugdevelopment comes in a game-changer for millions of people around the world. The Growing Importance of Generic DrugDevelopment As the global demand for affordable medications continues to rise, the importance of generic drugdevelopment cannot be overstated.
s Mark Tobolowsky co-authored the peer-reviewed article “ Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials ” in the recently published edition of Human Gene Therapy. Hyman, Phelps & McNamara, P.C.’s
Artificial Intelligence (AI) is poised to transform the field of target discovery in drugdevelopment, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds.
Sujeegar Jeevanandam, an expert with 13 years of experience in life sciences R&D, offers valuable insights into the current state and future trajectory of artificial intelligence in drug discovery. This breakthrough could fundamentally change how drugs are developed and tested.
It’s essential for maintaining ethical standards, high-quality outcomes and facilitating global standardisation, enabling multi-center and multinational studies, thereby streamlining the development and approval process for new medical treatments, and maintaining public trust in clinical research.
Image credit: Crystal Eye Media / Shutterstock The role of SPICA and manufacturing capabilities Drugdevelopment in the radiopharmaceutical space is particularly resource intensive. He stresses the importance of recognising organisational strengths and weaknesses: “No single company is fully expert in all aspects of drugdevelopment.”
In the high-stakes world of pharmaceuticals, patents play a pivotal role in safeguarding intellectual property and ensuring a return on investment for drugdevelopers. The journey of a drug patent is a complex and intricate one, spanning from the initial filing to its eventual expiry.
Drugdevelopment is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.
On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drugdevelopment, starting with monoclonal antibodies (mAbs).[ from approved products in other countries) to inform doses and development. Legislation with delayed implementation In 2021, the FDA Modernization Act 2.0
One area drawing increasing attention is how these changes will affect the drugdevelopment and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a leadership vacuum at the Center for Drug Evaluation and Research (CDER).
In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drugdevelopers for phase I trials, second only to navigating regulatory compliance (- 38 percent). Silver Spring (MD): Food and Drug Administration (US); 2016-. 113:9861002.
ABSTRACT Infectious diseases, including bacterial, fungal, and viral, have once again gained urgency in the drugdevelopment pipeline after the recent COVID-19 pandemic. Compound 26 was identified as a promising antiproliferative hit. Tuberculosis (TB) is an old infectious disease for which eradication has not yet been successful.
Generic drugdevelopment is a complex process that requires a deep understanding of regulatory requirements and guidelines. Regulatory expertise plays a crucial role in ensuring that generic drugs meet the necessary standards for quality, safety, and efficacy. ” Scientific Research Publishing , 2024. ” U.S.
Recent advancements in analytical technologies have significantly impacted the development of generic drugs, enabling more accurate and efficient analysis of complex drug products. This article will explore the latest developments in… Source
Five Promising Treatment Areas in Early-Phase DrugDevelopment in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drugdevelopment is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
In this article, we'll delve into the world of drafting drug patent applications for biologic drugs. To draft a strong patent application, you need to understand the nuances of biologic drugdevelopment, including the production process, stability, and formulation. Read the full article here: [link]
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content